A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma

Vista sencilla de ítem
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorRojas Puentes, Leonardo
dc.contributor.authorWills, Beatriz
dc.contributor.authorRuíz-Patiño, Alejandro
dc.contributor.authorAbril, Lina Alejandra
dc.contributor.authorJiménez, Encarnación
dc.contributor.authorUseche, Nicolás
dc.contributor.authorBermúdez, Sonia
dc.contributor.authorMejia, Juan Alberto
dc.contributor.authorRamón, Juan Fernando
dc.contributor.authorCarranza Isaza, Hernán
dc.contributor.authorVargas, César
dc.contributor.authorOtero, Jorge
dc.contributor.authorArchila, Pilar
dc.contributor.authorRodríguez, Jaime
dc.contributor.authorBehaine, José
dc.contributor.authorGonzález, Daniel
dc.contributor.authorJacobo, Juan
dc.contributor.authorCifuentes, Héctor
dc.contributor.authorFeo, Oscar
dc.contributor.authorPenagos, Pedro
dc.contributor.authorPineda, David
dc.contributor.authorRicaurte, Luisa María
dc.contributor.authorPino, Luis Eduardo
dc.contributor.authorVargas, Carlos Andrés
dc.contributor.authorMárquez, Joana
dc.contributor.authorMantilla, Monica
dc.contributor.authorOrtiz, Leon D.
dc.contributor.authorBalaña, Carme
dc.contributor.authorRosell, Rafael
dc.contributor.authorZatarain-Barrón, Zyanya Lucia
dc.contributor.authorArrieta, Oscar
dc.contributor.authorHakim, Fernando
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.contributor.orcidCarranza Isaza, Hernán [0000-0002-3593-7405]
dc.contributor.orcidRojas Puentes, Leonardo [0000-0002-7865-5424]
dc.contributor.orcidRuíz-Patiño, Alejandro [0000-0003-1274-9273]
dc.date.accessioned2020-03-09T13:42:44Z
dc.date.available2020-03-09T13:42:44Z
dc.date.issued2019
dc.description.abstractenglishPurpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis, with survival ranging from 25 to 40 weeks. Antiangiogenic agents are widely used, showing a variable response. In this study, we explored the efcacy of carmustine plus bevacizumab (BCNU/Bev) for treating rGBM. Methods/patients In this study, we assessed 59 adult patients with histologically confrmed rGBM who were treated with BCNU/Bev as second-line regimen. The response rate (RR), progression-free survival (PFS) and overall survival (OS) were evaluated according to their molecular expression profle, including CD133 mRNA expression, MGMT methylation (pMGMT), PDGFR amplifcation, YKL40 mRNA expression, IDH1/2 condition, p53 and EGFRvIII mutation status. Results Median follow-up was 18.6 months, overall RR to the combination was 56.3%, and median PFS was 9.0 months (95% CI 8.0–9.9). OS from time of diagnosis was 21.0 months (95% CI 13.2–28.7) and from starting BCNU/Bev it was 10.7 months (95% CI 9.5–11.8). IDH1/2 mutations were found in 30.5% of the patients, pMGMT in 55.9% and high CD133 mRNA expression in 57.6%. Factors which positively afected PFS included performance status (p=0.015), IDH+ (p=0.05), CD133 mRNA expression (p=0.009) and pMGMT+ (p=0.007). OS was positively afected by pMGMT+ (p=0.05). Meanwhile, YKL40 negatively afected PFS (p=0.01) and OS (p=0.0001). Grade≥3 toxicities included hypertension (22%) and fatigue (12%). Conclusions BCNU/Bev is a safe and tolerable treatment for rGBM. Patients with MGMT+/IDH+ derive the greatest beneft from the treatment combination in the second-line setting. Nonetheless, high YKL40 expression discourages the use of antiangiogenic therapy.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1007/s12094-019-02066-2
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1699-048X
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/2018
dc.language.isoeng
dc.publisherSpringerspa
dc.publisher.journalClinical and Translational Oncologyspa
dc.relation.ispartofseriesClinical and Translational Oncology, 1699-048X, Vol. 21, 2019, p.1364-1373spa
dc.relation.urihttps://link.springer.com/article/10.1007%2Fs12094-019-02066-2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf61
dc.rights.creativecommons2019
dc.rights.localAcceso cerradospa
dc.subject.decsNeoplasias neuroepitelialesspa
dc.subject.decsAnticuerpos monoclonalesspa
dc.subject.decsImpresión molecularspa
dc.subject.keywordsGlioblastomaspa
dc.subject.keywordsSecond-line therapyspa
dc.subject.keywordsBevacizumabspa
dc.subject.keywordsMolecular expression classifcationspa
dc.titleA comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastomaspa
dc.title.translatedA comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartículospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Cardona, Andres.pdf
Tamaño:
1.03 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos